Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.0711741105
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Structure-Guided Discovery of a Selective McL1 Inhibitor With Cellular Activity

English

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Discovery of WAY-260022, a Potent and Selective Inhibitor of the Norepinephrine Transporter

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2010English

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Cancer Research
Cancer ResearchOncology
2018English

Diacylglycerol Kinase Η Augments C-Raf Activity and B-Raf/C-Raf Heterodimerization

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Small-Molecule P21-Activated Kinase Inhibitor PF-3758309 Is a Potent Inhibitor of Oncogenic Signaling and Tumor Growth

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy